This page uses content from Wikipedia and is licensed under CC BY-SA.

Imagabalin

Imagabalin
Imagabalin.svg
Clinical data
SynonymsPD-0332334; PD-332,334
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
KEGG
Chemical and physical data
FormulaC9H19NO2
Molar mass173.253 g/mol g·mol−1
3D model (JSmol)

Imagabalin (INN, USAN; PD-332,334) is a drug which acts as a ligand for the α2δ subunit of the voltage-dependent calcium channel,[1] with some selectivity for the α2δ1 subunit over α2δ2.[2] Under development by Pfizer as a pharmaceutical medication, it has demonstrated preclinical efficacy of anxiolytic, analgesic, hypnotic, and anticonvulsant-like activity and is currently in phase III clinical trials for the treatment of generalized anxiety disorder.[2][3]

See also

References

  1. ^ Quintero JE, Pomerleau F, Huettl P, Johnson KW, Offord J, Gerhardt GA (July 2011). "Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: basic characterization and drug pharmacology". Brain Research. 1401: 1–9. doi:10.1016/j.brainres.2011.05.025. PMC 3197737. PMID 21664606.
  2. ^ a b Larry Ereshefsky (2008). "Therapies in the Pipeline for Sleep Disorders: Focus on Novel Mechanisms and Disease Models" (PDF) (Press release). p. 11. Retrieved 2012-04-22.
  3. ^ "A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder". Retrieved 2012-04-22.